Ozempic® lowers fasting and postprandial blood glucose by stimulating insulin secretion in a very glucose-dependent manner.1Now, the FDA has only offered acceptance to Wegovy, two.4 mg, subcutaneous semaglutide, being an antiobesity medication.seven Down the road, it could be effective to take a look at oral semaglutide as being a weight loss med